[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002098455A3 - Production of recombinant human arylsulfatase a - Google Patents

Production of recombinant human arylsulfatase a Download PDF

Info

Publication number
WO2002098455A3
WO2002098455A3 PCT/DK2002/000387 DK0200387W WO02098455A3 WO 2002098455 A3 WO2002098455 A3 WO 2002098455A3 DK 0200387 W DK0200387 W DK 0200387W WO 02098455 A3 WO02098455 A3 WO 02098455A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
seq
cell
recombinant human
expression
Prior art date
Application number
PCT/DK2002/000387
Other languages
French (fr)
Other versions
WO2002098455A2 (en
WO2002098455A8 (en
Inventor
Jens Fogh
Meher Irani
Claes Andersson
Cecilia Weigelt
Original Assignee
Hemebiotech As
Jens Fogh
Meher Irani
Claes Andersson
Cecilia Weigelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemebiotech As, Jens Fogh, Meher Irani, Claes Andersson, Cecilia Weigelt filed Critical Hemebiotech As
Priority to AU2002317700A priority Critical patent/AU2002317700A1/en
Publication of WO2002098455A2 publication Critical patent/WO2002098455A2/en
Publication of WO2002098455A8 publication Critical patent/WO2002098455A8/en
Publication of WO2002098455A3 publication Critical patent/WO2002098455A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a cell capable of producing recombinant human ASA, said cell comprising the DNA fragment shown in SEQ ID NO 1. In particular, the invention relates to a cell comprising the 1578 basepair EcoRI - XbaI fragment of the DNA fragment shown in SEQ ID NO 2. One embodiment of the invention relates to an expression plasmid pAsaExp1 as show in SEQ ID NO 2 for use in the expression of rhASA in cells. Further, the invention relates to a method for the preparation of recombinant human ASA, the method comprising a) introducing, into a suitable vector, a nucleic acid fragment comprising the DNA fragment shown in SEQ ID NO 1, b) transforming a cell with the vector obtained in step a), c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence, d) recovering the expression product from the culture. Optionally, the method may further comprise a fermentation step and/or purification step. The invention further relates to a rhASA produced by the method of the invention and to the use of the rhASA produced for the preparation of a medicament for the treatment of Metachromatic Leukodystrophy.
PCT/DK2002/000387 2001-06-07 2002-06-07 Production of recombinant human arylsulfatase a WO2002098455A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002317700A AU2002317700A1 (en) 2001-06-07 2002-06-07 Production of recombinant human arylsulfatase a

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29611201P 2001-06-07 2001-06-07
US60/296,112 2001-06-07

Publications (3)

Publication Number Publication Date
WO2002098455A2 WO2002098455A2 (en) 2002-12-12
WO2002098455A8 WO2002098455A8 (en) 2003-02-13
WO2002098455A3 true WO2002098455A3 (en) 2004-03-25

Family

ID=23140660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000387 WO2002098455A2 (en) 2001-06-07 2002-06-07 Production of recombinant human arylsulfatase a

Country Status (2)

Country Link
AU (1) AU2002317700A1 (en)
WO (1) WO2002098455A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210936C1 (en) * 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005073367A1 (en) * 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a
NZ568728A (en) * 2006-04-04 2011-09-30 Shire Pharmaceuticals Ireland Ltd A process for concentration of a aryl sulfatase A
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
ES2625511T3 (en) * 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
BR112015015948B1 (en) 2013-01-09 2022-05-17 Takeda Pharmaceutical Company Limited METHOD OF PURIFICATION OF RECOMBINANT ARYLSULPHATASE A (ASA) PROTEIN
BR112021021908A2 (en) 2019-05-03 2022-02-01 Univ Pennsylvania Useful compositions in the treatment of metachromatic leukodystrophy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
WO2001019955A2 (en) * 1999-09-14 2001-03-22 Canfield William M Lysosomal targeting pathway enzymes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004001A1 (en) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
WO2001019955A2 (en) * 1999-09-14 2001-03-22 Canfield William M Lysosomal targeting pathway enzymes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SANGALLI A ET AL: "TRANSDUCED FIBROBLAST AND METACHROMATIC LEUKODYSTROPHY LYMPHOCYTES TRANSFER ARYLSULFATASE A TO MYELINATING GLIA AND DEFICIENT CELLS IN VITRO", HUMAN GENE THERAPY, vol. 9, no. 14, 20 September 1998 (1998-09-20), pages 2111 - 2119, XP001041995, ISSN: 1043-0342 *
STEIN C ET AL: "CLONING AND EXPRESSION OF HUMAN ARYLSULFATASE A", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 264, no. 2, 15 January 1989 (1989-01-15), pages 1252 - 1259, XP002185735 *

Also Published As

Publication number Publication date
AU2002317700A1 (en) 2002-12-16
WO2002098455A2 (en) 2002-12-12
WO2002098455A8 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
RU2206611C2 (en) DNA FRAGMENT, PLASMID VECTOR, METHOD FOR PREPARING POLYPEPTIDE AND POLYPEPTIDE ELICITING IL-1β PROTEASE ACTIVITY
WO2003008615A3 (en) Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced succ or sucd gene
WO2003033519A3 (en) Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
WO2006073846A3 (en) Methods for expression and purification of recombinant human growth hormone
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
WO2002098455A3 (en) Production of recombinant human arylsulfatase a
DE502004000547D1 (en) Process for the fermentative production of L-methionine
WO2002081721A3 (en) Process for the production of l-amino acids using strains of the family enterobacteriaceae that contain an attenuated dgsa gene
IL202280A (en) Codon-optimized fsh-coding nucleic acid and use thereof for recombinant fsh production
EP1364966A3 (en) Production of recombinant human epidermal growth factor in plants
ATE542913T1 (en) PROMOTOR VARIANTS FOR EXPRESSING GENES IN A FUNGAL CELL
WO2001096527A3 (en) Peptides with physiological activity
WO2002014471A3 (en) A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
WO2002086137A3 (en) Process for the production of l-amino acids by fermentation using coryneform bacteria
WO2003000881A3 (en) Method of plasmid stabilisation by in vivo deleting the antibiotic resistence and selecting with an essential gene
ES2229250T3 (en) PROCEDURE FOR THE USE OF THE PA-ADH PROMOTING SYSTEM IN A YEAST FOR THE BIIOTECHNOLOGICAL PRODUCTION OF HETEROLOGICAL PROTEINS IN HIGH PERFORMANCES.
WO2002099092A3 (en) Production of recombinant human lysosomal alpha-mannosidase
PL2207795T3 (en) Process for producing mature recombinant mite group i allergen
CA3208244A1 (en) Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses
CA3170281A1 (en) Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses
EP1262551A3 (en) A sorbitol dehydrogenase gene, a recombinant DNA, and a process for producing sorbitol dehydrogenase
DE602005019421D1 (en) MOST SUITABLE MICROORGANISM
CN105861406A (en) Transgenic agrobacterium strain for expressing recombined human albumin genes in plants
WO2021175960A1 (en) Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses
WO2009057622A1 (en) Method for production of human growth hormone improved in efficiency

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 50/2002 UNDER "PUBLISHED" DELETE "WITHOUT (AN) INDICATION(S) IN RELATION TO DEPOSITED BIOLOGICAL MATERIAL FURNISHED UNDER RULE 13BIS SEPARATELY FROM THE DESCRIPTION"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP